Iovance Biotherapeutics
IOVA
86 hedge funds and large institutions have $325M invested in Iovance Biotherapeutics in 2015 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 11 closing their positions.
327% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 11
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
72% more funds holding
Funds holding: 50 → 86 (+36)
4% more capital invested
Capital invested by funds: $313M → $325M (+$12M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
65% less call options, than puts
Call options by funds: $439K | Put options by funds: $1.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
+$18.7M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$13.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$10M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Ayer Capital Management
San Francisco,
California
|
-$31M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.42M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$642K |
| 4 |
Goldman Sachs
New York
|
-$425K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$416K |
IOVA Hedge Fund Activity: Q2 2015 in Review
86 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2015, worth a combined $325M — up 3.8% from $313M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new IOVA positions and 11 closed out — a net gain of 36 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was RS Investment Management, opening a new position worth an estimated $18.7M. The largest seller was Ayer Capital Management, cutting an estimated $31M.
- 86 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2015, up from 50 in Q1 2015.
- Funds reported $325M of Iovance Biotherapeutics stock for Q2 2015, up 3.8% quarter-over-quarter.
- 47 funds opened new Iovance Biotherapeutics positions in Q2 2015 and 11 closed out, a net change of +36 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2015 was RS Investment Management, an estimated $18.7M added.
- The largest Iovance Biotherapeutics seller in Q2 2015 was Ayer Capital Management, an estimated $31M sold.
Based on aggregated 13F filings for Q2 2015.